Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
228.3 EUR | -1.17% | +59.42% | +31.55% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.55% | 31.24B | - | ||
+38.65% | 39.1B | A | ||
-7.66% | 38.76B | B | ||
+13.09% | 25.9B | B- | ||
-13.50% | 25.8B | C | ||
+45.94% | 14.06B | B+ | ||
+39.15% | 13.12B | C+ | ||
-6.87% | 11.32B | B+ | ||
-11.87% | 10.68B | C+ | ||
-7.58% | 9.12B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALNY Stock
- DUL Stock
- Ratings Alnylam Pharmaceuticals, Inc.